$$VEEV top growth stock

Excellent growth stock with SaaS for pharmaceutical companies.


Veeva shares top billing among cloud-based medical software stocks with Athenahealth (ATHN) and Medidata Solutions (MDSO). The group ranks No. 4 among the 197 industries

Based in the San Francisco Bay Area, Veeva Systems develops cloud-based software for the life sciences industry. In addition to medical customer relationship management (CRM) solutions, Veeva’s software helps clients manage clinical data, regulatory compliance, and quality control.

From the largest Big Pharma companies to emerging biotechs, Veeva has more than 625 customers around the world. Its client roster includes GlaxoSmithKline (GSK), AstraZeneca (AZN), Biogen (BIIB), Bayer (BAYRY), Merck (MRK) and Novartis (NVS).

Veeva sports strong annual three-year growth rates for both earnings (37%) and revenue (30%). The company also sports a 32% annual pretax profit margin and an 19% return on equity.

Working on a flat base with $85.10 buy point. Good support at the 50dma while building this base and relative strength new a high.

Earnings 8/22.
Ranked #1 in its group, which is ranked #4
Very strong relative growth rankings
ChecklistRating
Composite Rating 99 Pass
EPS Rating 93 Pass
RS Rating 89 Pass
Group RS Rating A+ Pass
SMR Rating A Pass
Acc/Dis Rating B- Pass

EPS %change last Q was 43%
no debt
Qtrs Of Increasing Fund Ownership 2

If it breaks past the buy point on strong volume, it could be a good time to add to existing holdings or commit to a new stake if you like the company.

P.

17 Likes

I see a company with slower revenue growth than ADBE and MSFT, trading at a higher valuation. What gives?

1 Like

I see a company with slower revenue growth than ADBE and MSFT, trading at a higher valuation. What gives?

VEEV’s revenue growth has actually been a little greater than ADBE’s and double that of MSFT - although revenue growth is expected to be comparable to ADBE’s this year.

VEEV is a small cap growth stock about 1/10 the market cap of ADBE and 1/70 the market cap of MSFT. It has much greater growth potential along with greater risk.

It has a strong competitive position in its life sciences niche.

dave

VEEV’s revenue growth has actually been a little greater than ADBE’s and double that of MSFT

This past Q it was below both. I’m not interested in 2017’s growth.

It has a strong competitive position in its life sciences niche.

Sure, maybe, but nothing like Adobe’s monopoly in their space.

1 Like

Veev blew out earnings last week and was up 12%. Their Vault subscription count is growing rapidly. They are the best in class and are growing, but way to extended to buy now.

P.